HUTCHMED (China) Limited or Celldex Therapeutics, Inc.: Who Leads in Yearly Revenue?

Biotech Revenue Battle: HUTCHMED vs. Celldex

__timestamp	Celldex Therapeutics, Inc.	HUTCHMED (China) Limited
Wednesday, January 1, 2014	3586000	91813000
Thursday, January 1, 2015	5480000	178203000
Friday, January 1, 2016	6786000	216080000
Sunday, January 1, 2017	12743000	241203000
Monday, January 1, 2018	9538000	214109000
Tuesday, January 1, 2019	3573000	204890000
Wednesday, January 1, 2020	7418000	227976000
Friday, January 1, 2021	4651000	356128000
Saturday, January 1, 2022	2357000	426409000
Sunday, January 1, 2023	6883000	837999000

Infusing magic into the data realm

Revenue Race: HUTCHMED vs. Celldex

In the competitive landscape of biotechnology, revenue growth is a key indicator of success. Over the past decade, HUTCHMED (China) Limited has consistently outpaced Celldex Therapeutics, Inc. in annual revenue. From 2014 to 2023, HUTCHMED's revenue surged by over 800%, reaching a peak of approximately $838 million in 2023. In contrast, Celldex's revenue fluctuated, peaking at around $12.7 million in 2017, but declining to $6.9 million by 2023.

A Decade of Growth

HUTCHMED's impressive growth trajectory highlights its strategic positioning in the market, with a steady increase in revenue year-on-year. Meanwhile, Celldex's revenue trends suggest a more volatile journey, with significant peaks and troughs. This comparison underscores the dynamic nature of the biotech industry, where strategic decisions and market conditions can dramatically impact financial outcomes.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025